摘要
目的 探讨miR-5585-3p在弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达与临床病理特征的相关性及其预后意义。方法 选取12例DLBCL石蜡标本进行基因芯片扫描,依据foldchange≥1.5、P≤0.05筛选出差异性表达的miRNAs,miR-5585-3p是其中之一。采用qRT-PCR检测95例DLBCL石蜡标本中miR-5585-3p的表达,15例淋巴结反应性增生组织作为对照,并结合患者临床病理学资料进行分析。结果 miR-5585-3p在DLBCL中的表达量显著高于淋巴结反应性增生组织(P〈0.001),且non-GCB亚型miR-5585-3p的表达水平是GCB型的2.4倍(P=0.006)。miR-5585-3p高表达与淋巴瘤国际预后指数(IPI)呈正相关(P=0.005)。Kaplan-Meier生存分析显示:DLBCL中高表达miR-5585-3p的患者生存率明显低于miR-5585-3p低表达者(P=0.049)。预后多因素Cox分析显示,年龄〉60岁(P=0.010)、IPI评分3~5分(P=0.004)、高表达miR-5585-3p(P=0.014)为DLBCL独立不良预后指标。结论 miR-5585-3p高表达可能与DLBCL不良预后有关。
Purpose To investigate the expression of miR-5585-3p in diffuse large B-cell lymphoma (DLBCL) and its relevance with clinical pathological features, prognostic significance in clinical practice. Methods Altered expression of miRNAs was identified by microarray in an initial 12 DLBCL cases by using fold change ≥ 1.5, P≤0.05 as cutoff value, miR-5585-3p was one of them. The miR-5585-3p expression was confirmed by qRT-PCR in 95 DLBCL samples and 15 samples of reactive hyperplasia as controls. The clinical pathological data of patients were analyzed with the miR-5585-3p expression. Results The expression level of miR-5585-3p was significantly higher in DLBCL patients than in reactive hyperplasia samples ( P 〈 0. 001 ) , and the expression of miR-5585-3p in non-GCB was 2.4 times as much as that in GCB subtypes (P =0. 006). Positive correlation was observed between the rniR-5585-3p expression level and IPI score ( P = 0. 005 ). Kaplan-Meier analysis showed that higher expression level of miR-5585-3p was signifi- cantly associated with a poorer overall survival compared with lower expression of miR-5585-3p in DLBCL patients ( P = 0. 049). Mult- ivariahle Cox regression revealed the age 〉60 (P =0. 010) , IPI score 3-5 (P =0. 004) , higher expression miR-5585-3p (P =0. 014) were independent poor prognostic factors of DLBCL. Conclusion The higher expression of miR-5585-3p in DLBCL might be relative to the poor prognosis of DLBCL.
出处
《临床与实验病理学杂志》
CAS
CSCD
北大核心
2016年第2期152-156,共5页
Chinese Journal of Clinical and Experimental Pathology
基金
安徽省自然科学基金(1608085MH228)
杨森科学研究基金(JRCC2012肿瘤01)